MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Preexisting evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.Journal of the National Cancer Institute · 2023
   Pooled it
2. Cell-context response to germ layer differentiation signals is predetermined by the epigenome in regionalized epiblast populations.Nature communications · 2025
   Article
3. Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma.Heliyon · 2023
   Article
4. Construction and Validation of a Protein-associated Prognostic Model for Gastrointestinal Cancer.Combinatorial chemistry & high throughput screening · 2023
   Article
5. ROS/JNK/C-Jun Pathway is Involved in Chaetocin Induced Colorectal Cancer Cells Apoptosis and Macrophage Phagocytosis Enhancement.Frontiers in pharmacology · 2021
   Article
6. Immunotherapy in colorectal cancer: current achievements and future perspective.International journal of biological sciences · 2021
   Review
7. Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?Translational gastroenterology and hepatology · 2019
   Review

Corrections and comments

• Comment on
  Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as